

NCCN. Clinical Practice Guidelines in Oncology. Breast cancer, version 5.2025.
Accessed January 2, 2026.

https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Turner NC et al. N Engl J Med. 2024;391(17):1584-1596

Fonana F et al. Int J Biol Sci. 2024;20(8):3113-3125.

Andre F et al. N Engl J Med. 2019;380(20):1929-1940

Andre F et al. Ann Oncol. 2021;32(2):208-217

Turner NC et al. N Engl J Med. 2023;388(22):2058-2070.

Turner NC et al. N Engl J Med. 2024;391(17):1584-1596.

Jhaveri K et al. N Engl J Med. 2025;393(2): 151-161.

Jesselsohn R et al. Curr Oncol Rep. 2017;19(35):35; Jesselsohn R et al. Cancer Cell. 2018;33(2):173-186.

Bidard FC et al. J Clin Oncol. 2022;40(28):3246-3256.

Jhaveri KL et al. J Clin Oncol. 2024;42(35):4173-4186

Jhaveri KL et al. N Engl J Med. 2024.

Jhaveri K et al. SABCS. Abstract SESS-3617

Jhaveri K et al. Ann Oncol. 2025; S0923-7534(25)06289-1

Jhaveri K et al. SABCS. 2025. GS3-08

Oliveira M et al. Lancet Oncol. 2024;25(11):1424-1439

Bidard FC et al. N Engl J Med. 2025;393:569-580

Pfizer Oncology. <https://www.pfizeroncologydevelopment.com/molecule/protac-estrogen-receptor-degrader>. Accessed 2 January 2026.

Campone M et al. N Engl J Med. 2025;393(6):556-568